Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi, Lonza JV Should Offer Pair Flexibility In Biologics Manufacturing

Executive Summary

The pair's pact to build a biologics manufacturing site in Switzerland will allow Sanofi to expand or contract capacity usage in response to demand for its future biological therapies and give Lonza the option to pick up any eventual slack.

You may also be interested in...



Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Sanofi R&D Chief Zerhouni: How I'm Doing More With Less

Elias Zerhouni says Sanofi's ongoing R&D revamp has produced improved innovative results with controlled spending, in part by emphasizing cutting-edge product development ahead of research.

Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling

Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.

Topics

Related Companies

UsernamePublicRestriction

Register

SC098304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel